Probiotics for prevention of urinary stones

Annals of Translational Medicine

Volumn 5, Issue 2, 2017, Pages

  Lieske, John C ^a  

^a MAYO CLINIC   (United States)

Author keywords

Calcium oxalate (CaOx); Lactobacilli; Microbiome; Nephrolithiasis; Oxalobacter formigenes

Indexed keywords

OXALIC ACID; PLACEBO; PROBIOTIC AGENT;

ARTICLE; BACTERIAL COLONIZATION; BACTERIAL STRAIN; BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS; CLINICAL EFFECTIVENESS; DISEASE ASSOCIATION; DRUG EFFICACY; HUMAN; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS BREVIS; NONHUMAN; OXALOBACTER FORMIGENES; RANDOMIZED CONTROLLED TRIAL (TOPIC); STREPTOCOCCUS THERMOPHILUS; SYSTEMATIC REVIEW; TREATMENT DURATION; URINARY EXCRETION; UROLITHIASIS;

EID: 85010635895     PISSN: 23055839     EISSN: 23055847     Source Type: Journal    
DOI: 10.21037/atm.2016.11.86     Document Type: Article

References (39)

1. Lieske JC, Rule AD, Krambeck AE, et al. Stone composition as a function of age and sex. Clin J Am Soc Nephrol 2014;9:2141-6.
2. Wang X, Krambeck AE, Williams JC Jr, et al. Distinguishing characteristics of idiopathic calcium oxalate kidney stone formers with low amounts of Randall's plaque. Clin J Am Soc Nephrol 2014;9:1757-63.
3. Evan AP, Coe FL, Lingeman JE, et al. Mechanism of formation of human calcium oxalate renal stones on Randall's plaque. Anat Rec (Hoboken) 2007;290:1315-23.
4. Evan AP, Lingeman J, Coe F, et al. Renal histopathology of stone-forming patients with distal renal tubular acidosis. Kidney Int 2007;71:795-801.
5. Evan AP, Lingeman JE, Coe FL, et al. Intra-tubular deposits, urine and stone composition are divergent in patients with ileostomy. Kidney Int 2009;76:1081-8.
6. Asplin JR, Parks JH, Chen MS, et al. Reduced crystallization inhibition by urine from men with nephrolithiasis. Kidney Int 1999;56:1505-16.
7. Asplin JR, Parks JH, Nakagawa Y, et al. Reduced crystallization inhibition by urine from women with nephrolithiasis. Kidney Int 2002;61:1821-9.
8. Lieske JC, Norris R, Swift H, et al. Adhesion, internalization and metabolism of calcium oxalate monohydrate crystals by renal epithelial cells. Kidney Int 1997;52:1291-301.
9. Moe OW, Bonny O. Genetic hypercalciuria. J Am Soc Nephrol 2005;16:729-45.
10. Pak CY. A critical evaluation of treatment of calcium stones. Adv Exp Med Biol 1980;128:451-65.
11. Lieske JC, Turner ST, Edeh SN, et al. Heritability of dietary traits that contribute to nephrolithiasis in a cohort of adult sibships. J Nephrol 2016;29:45-51.
12. Edvardsson VO, Goldfarb DS, Lieske JC, et al. Hereditary causes of kidney stones and chronic kidney disease. Pediatr Nephrol 2013;28:1923-42.
13. Holmes RP, Goodman HO, Assimos DG. Contribution of dietary oxalate to urinary oxalate excretion. Kidney Int 2001;59:270-6.
14. Hesse A, Schneeberger W, Engfeld S, et al. Intestinal hyperabsorption of oxalate in calcium oxalate stone formers: application of a new test with [13C2]oxalate. J Am Soc Nephrol 1999;10 Suppl 14:S329-33.
15. Hatch M, Freel RW. Intestinal transport of an obdurate anion: oxalate. Urol Res 2005;33:1-16.
16. Jiang Z, Asplin JR, Evan AP, et al. Calcium oxalate urolithiasis in mice lacking anion transporter Slc26a6. Nat Genet 2006;38:474-8.
17. Freel RW, Hatch M, Green M, et al. Ileal oxalate absorption and urinary oxalate excretion are enhanced in Slc26a6 null mice. Am J Physiol Gastrointest Liver Physiol 2006;290:G719-28.
18. Hatch M, Cornelius J, Allison M, et al. Oxalobacter sp. reduces urinary oxalate excretion by promoting enteric oxalate secretion. Kidney Int 2006;69:691-8.
19. Worcester EM, Evan AP, Coe FL, et al. A test of the hypothesis that oxalate secretion produces proximal tubule crystallization in primary hyperoxaluria type I. Am J Physiol Renal Physiol 2013;305:F1574-84.
20. Stauffer JQ. Hyperoxaluria and intestinal disease. The role of steatorrhea and dietary calcium in regulating intestinal oxalate absorption. Am J Dig Dis 1977;22:921-8.
21. Curhan GC, Willett WC, Speizer FE, et al. Comparison of dietary calcium with supplemental calcium and other nutrients as factors affecting the risk for kidney stones in women. Ann Intern Med 1997;126:497-504.
22. Pearle MS, Goldfarb DS, Assimos DG, et al. Medical management of kidney stones: AUA guideline. J Urol 2014;192:316-24.
23. Ryall RL. Urinary inhibitors of calcium oxalate crystallization and their potential role in stone formation. World J Urol 1997;15:155-64.
24. Zuckerman JM, Assimos DG. Hypocitraturia: pathophysiology and medical management. Rev Urol 2009;11:134-44.
25. Sakhaee K, Williams RH, Oh MS, et al. Alkali absorption and citrate excretion in calcium nephrolithiasis. J Bone Miner Res 1993;8:789-94.
26. Lieske JC, Tremaine WJ, De Simone C, et al. Diet, but not oral probiotics, effectively reduces urinary oxalate excretion and calcium oxalate supersaturation. Kidney Int 2010;78:1178-85.
27. Ferraz RR, Marques NC, Froeder L, et al. Effects of Lactobacillus casei and Bifidobacterium breve on urinary oxalate excretion in nephrolithiasis patients. Urol Res 2009;37:95-100.
28. Lieske JC, Goldfarb DS, De Simone C, et al. Use of a probiotic to decrease enteric hyperoxaluria. Kidney Int 2005;68:1244-9.
29. Argenzio RA, Liacos JA, Allison MJ. Intestinal oxalate-degrading bacteria reduce oxalate absorption and toxicity in guinea pigs. J Nutr 1988;118:787-92.
30. Campieri C, Campieri M, Bertuzzi V, et al. Reduction of oxaluria after an oral course of lactic acid bacteria at high concentration. Kidney Int 2001;60:1097-105.
31. Goldfarb DS, Modersitzki F, Asplin JR. A randomized, controlled trial of lactic acid bacteria for idiopathic hyperoxaluria. Clin J Am Soc Nephrol 2007;2:745-9.
32. Jiang J, Knight J, Easter LH, et al. Impact of dietary calcium and oxalate, and Oxalobacter formigenes colonization on urinary oxalate excretion. J Urol 2011;186:135-9.
33. Kaufman DW, Kelly JP, Curhan GC, et al. Oxalobacter formigenes may reduce the risk of calcium oxalate kidney stones. J Am Soc Nephrol 2008;19:1197-203.
34. Siener R, Bangen U, Sidhu H, et al. The role of Oxalobacter formigenes colonization in calcium oxalate stone disease. Kidney Int 2013;83:1144-9.
35. Hatch M, Gjymishka A, Salido EC, et al. Enteric oxalate elimination is induced and oxalate is normalized in a mouse model of primary hyperoxaluria following intestinal colonization with Oxalobacter. Am J Physiol Gastrointest Liver Physiol 2011;300:G461-9.
36. Hoppe B, Beck B, Gatter N, et al. Oxalobacter formigenes: a potential tool for the treatment of primary hyperoxaluria type 1. Kidney Int 2006;70:1305-11.
37. Mogna L, Pane M, Nicola S, et al. Screening of different probiotic strains for their in vitro ability to metabolise oxalates: any prospective use in humans? J Clin Gastroenterol 2014;48 Suppl 1:S91-5.
38. Miller AW, Dearing D. The metabolic and ecological interactions of oxalate-degrading bacteria in the Mammalian gut. Pathogens 2013;2:636-52.
39. Miller AW, Kohl KD, Dearing MD. The gastrointestinal tract of the white-throated Woodrat (Neotoma albigula) harbors distinct consortia of oxalate-degrading bacteria. Appl Environ Microbiol 2014;80:1595-601.